{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:37:54Z","timestamp":1774039074027,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.lfs.2020.117646","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T01:58:01Z","timestamp":1586224681000},"page":"117646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2\/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy"],"prefix":"10.1016","volume":"252","author":[{"given":"Parvin","family":"Zamani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamshid Gholizadeh","family":"Navashenaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manouchehr","family":"Teymouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Mashreghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lfs.2020.117646_bb0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.lfs.2020.117646_bb0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00262-003-0443-2","article-title":"Derangement of immune responses by myeloid suppressor cells","volume":"53","author":"Serafini","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.lfs.2020.117646_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2051-1426-1-10","article-title":"Myeloid derived suppressor cells\u2013a new therapeutic target in the treatment of cancer","volume":"1","author":"Wesolowski","year":"2013","journal-title":"Journal for immunotherapy of cancer"},{"issue":"2","key":"10.1016\/j.lfs.2020.117646_bb0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.coi.2010.01.021","article-title":"Myeloid-derived suppressor cell heterogeneity and subset definition","volume":"22","author":"Peranzoni","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.lfs.2020.117646_bb0025","series-title":"Immune-Mediated Diseases","first-page":"213","article-title":"Myeloid-derived suppressor cells","author":"Nagaraj","year":"2007"},{"issue":"8","key":"10.1016\/j.lfs.2020.117646_bb0030","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00262-018-2175-3","article-title":"Targeting myeloid-derived suppressor cells for cancer immunotherapy","volume":"67","author":"Liu","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.lfs.2020.117646_bb0035","article-title":"Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.lfs.2020.117646_bb0040","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00262-013-1407-9","article-title":"Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma","volume":"62","author":"Ghansah","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"13","key":"10.1016\/j.lfs.2020.117646_bb0045","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-13-3596","article-title":"Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1\u2013PD-L1 axis","volume":"74","author":"Ding","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.lfs.2020.117646_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067904","article-title":"The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system","volume":"8","author":"Geary","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lfs.2020.117646_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010365","article-title":"Doxorubicin in combination with a small TGF\u03b2 inhibitor: a potential novel therapy for metastatic breast cancer in mouse models","volume":"5","author":"Bandyopadhyay","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lfs.2020.117646_bb0060","doi-asserted-by":"crossref","first-page":"R275","DOI":"10.1186\/bcr787","article-title":"Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2\/neu in a murine mammary carcinoma model","volume":"6","author":"Eralp","year":"2004","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.lfs.2020.117646_bb0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-011-1117-0","article-title":"Immunological effects of taxol and adryamicin in breast cancer patients","volume":"61","author":"Panis","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.lfs.2020.117646_bb0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.lfs.2020.117646_bb0075","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.lfs.2020.117646_bb0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lfs.2020.117646_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2045-080X.174930","article-title":"A comparison between liposomal and nonliposomal formulations of doxorubicin in the treatment of cancer: an updated review","volume":"7","author":"Ngan","year":"2016","journal-title":"Arch. Pharm. Pract."},{"issue":"2","key":"10.1016\/j.lfs.2020.117646_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.lfs.2020.117646_bb0095","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1158\/2326-6066.CIR-13-0098","article-title":"Chemoimmunotherapy using pegylated liposomal doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study","volume":"1","author":"Simpkins","year":"2013","journal-title":"Cancer immunology research"},{"issue":"8","key":"10.1016\/j.lfs.2020.117646_bb0100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2015.08.004","article-title":"Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models","volume":"17","author":"Rios-Doria","year":"2015","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.lfs.2020.117646_bb0105","first-page":"687","article-title":"Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2","volume":"5","author":"Cabanes","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.lfs.2020.117646_bb0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/1061186X.2017.1387788","article-title":"A nano-liposome vaccine carrying E75, a HER-2\/neu-derived peptide, exhibits significant antitumour activity in mice","volume":"26","author":"Arab","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2020.117646_bb0115","series-title":"P5 HER2\/neu-derived Peptide Conjugated to Liposomes Containing MPL Adjuvant as an Effective Prophylactic Vaccine Formulation for Breast Cancer","first-page":"54","volume":"355(1)","author":"Shariat","year":"2014"},{"issue":"10","key":"10.1016\/j.lfs.2020.117646_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185099","article-title":"Conjugated nanoliposome with the HER2\/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model","volume":"12","author":"Razazan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117646_bb0125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2019.04.019","article-title":"MPL nano-liposomal vaccine containing P5 HER2\/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer","volume":"303","author":"Zamani","year":"2019","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.lfs.2020.117646_bb0130","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.4049\/jimmunol.165.9.5133","article-title":"DNA vaccination against rat her-2\/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB\/c mice","volume":"165","author":"Rovero","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2020.117646_bb0135","series-title":"Optimizing Dosage of Ketamine and Xylazine in Murine echocardiography","first-page":"499","volume":"34(5\u20136)","author":"Xu","year":"2007"},{"issue":"1","key":"10.1016\/j.lfs.2020.117646_bb0140","article-title":"Trypan blue exclusion test of cell viability","volume":"21","author":"Strober","year":"1997","journal-title":"Current Prot. Immunol."},{"issue":"4","key":"10.1016\/j.lfs.2020.117646_bb0145","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/678511","article-title":"Interleukin 13\u2013and interleukin 17A\u2013induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution","volume":"4","author":"Park","year":"2014","journal-title":"Pulmonary circulations"},{"issue":"8","key":"10.1016\/j.lfs.2020.117646_bb0150","doi-asserted-by":"crossref","first-page":"F785","DOI":"10.1152\/ajprenal.00488.2015","article-title":"Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL\/6 mice","volume":"310","author":"Mulay","year":"2016","journal-title":"American Journal of Physiology-Renal Physiology"},{"issue":"1","key":"10.1016\/j.lfs.2020.117646_bb0155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1096\/fj.14-256503","article-title":"Heme oxygenase-2 deletion impairs macrophage function: implication in wound healing","volume":"29","author":"Bellner","year":"2014","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.lfs.2020.117646_bb0160","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.lfs.2020.117646_bb0165","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.intimp.2011.02.021","article-title":"Tumor-and organ-dependent infiltration by myeloid-derived suppressor cells","volume":"11","author":"Younos","year":"2011","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.lfs.2020.117646_bb0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"14","key":"10.1016\/j.lfs.2020.117646_bb0175","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","article-title":"Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors","volume":"71","author":"Mattarollo","year":"2011","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.lfs.2020.117646_bb0180","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lfs.2020.117646_bb0185","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell\u2013dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.lfs.2020.117646_bb0190","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.lfs.2020.117646_bb0195","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1002\/jcp.26361","article-title":"Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy","volume":"233","author":"Zamani","year":"2018","journal-title":"J. Cell. Physiol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520303945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520303945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:36:02Z","timestamp":1758400562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520303945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":39,"alternative-id":["S0024320520303945"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117646","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2\/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117646"}}